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PHARMACOECONOMIC CLAIMS IN PRESCRIPTION DRUG
ADVERTISEMENTS IN FINNISH MEDICAL JOURNALS
Norjamäki A1, Martikainen J2,Turunen J2, Kivioja A1
1Ministry of Social Affairs and Health, Helsinki, Finland; 2University of
Kuopio, Kuopio, Finland
OBJECTIVES: To determine the number of pharmacoeconomic
messages in prescription drug advertisements in major Finnish
medical journals and whether their number has increased over
time. Additionally, to determine what kinds of claims these
advertisements include, whether supporting evidence is provided,
whether generic substitution has had an effect on the number
and which drugs were most frequently promoted. METHODS:
Prescription drug advertisements in three Finnish medical jour-
nals were examined. The ﬁrst issue published in January, July
and October in 1990–2003 was examined. All prescription drug
advertisements in the journals were counted and the ones with
economic messages were copied and analyzed with a structured
data collection form. RESULTS: There were 2175 advertise-
ments in the sample of 126 journals, of which 455 included 
economic and 294 quality of life—messages. The number of eco-
nomic content ads had increased from 19 in 1990 to 54 in 2003
(Pearson 0.75). The most frequently used economic claims were
cheap or economical and references to reimbursement or price.
The most often used quality of life claims were quality of life,
easy, good or better life or day or statements describing life (e.g.
balanced). Evidence for economic claims was found in 23% of
the advertisements and more than half of them referred to the
price list. Evidence for quality of life claims was found in 20%
of the ads and most of them referred to scientiﬁc studies. Generic
drugs were advertised most in 2001–2002, just before the generic
substitution was initiated in Finland. Economic messages were
most frequently used for antidepressants, ACE inhibitors and
anti-inﬂammatory drugs. CONCLUSIONS: 1) The number of
economic content advertisements has increased over time in
Finnish medical journals. 2) Evidence for the claims was found
in approximately 20% of the advertisements.
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BELIEFS ABOUT MEDICINES AMONG SWEDISH PHARMACY
EMPLOYEES
Jörgensen T,Andersson K, Mårdby AC
Göteborg University, Göteborg, Sweden
OBJECTIVES: Health professionals hold both professional and
personal health beliefs, and it is likely that this has an impact on
both which information one communicates and how. The impor-
tance of beliefs in relation to adherence to treatment has been
stressed, but is not yet fully appreciated by health professionals.
A larger project will analyse and compare beliefs about medi-
cines among health professionals and patients. The aim of this
study was to describe beliefs about medicines among pharmacy
employees. METHODS: The study was performed among phar-
macy employees at 24 community pharmacies in Göteborg,
Sweden. The participating pharmacies had a total of 372
employees (pharmacists, dispensing pharmacists, pharmacy tech-
nicians). Data collection was at the weekly pharmacy informa-
tion meetings with a questionnaire comprising background
questions (age, professional category, working experience and
medication use) and the general part of Beliefs about Medicines
Questionnaire (BMQ). RESULTS: A majority of the 292 respon-
dents were dispensing pharmacists. More than half of the respon-
dents were aged 45 years or older and had worked in a pharmacy
for 20 years or more. A higher proportion of dispensing phar-
macists stated current use of traditional medicines compared to
the other professional categories. The respondents had a high
mean value for General Beneﬁt and a low mean value for General
Harm. Compared to dispensing pharmacists, pharmacy techni-
cians viewed medicines as more harmful (p = 0.001); and com-
pared to pharmacy technicians, dispensing pharmacists regarded
medicines as more beneﬁcial (p = 0.001). When controlling for
background characteristics, no confounders were detected for
any of the three subscales. CONCLUSIONS: The reason for the
difference between dispensing pharmacists and technicians
remain unclear. Nevertheless, the positive beliefs among phar-
macy personnel may have an impact on the communication with
clients and, eventually, adherence.
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PUBLIC FUNDING OF DRUGS FOR ORPHAN DISEASES
Hughes D
University of Wales, Bangor, Gwynedd, UK
The EU regulation on orphan medicinal products aims to
promote the research and development of treatments for rare 
diseases. Approval by licensing authorities, however, does not
necessitate that health services reimburse such treatments.
OBJECTIVES: To assess whether cost-effectiveness analysis, as
conventionally applied, is appropriate for orphan drugs by con-
sidering whether availability of patients in the case of “ultra-
orphan” drugs is sufﬁcient for adequate statistical powering.
METHODS: Simulations of sample size for cost-effectiveness
analysis, based on Briggs & Tambour (1998) using the net-
beneﬁt approach, were conducted. Different values for costs and
beneﬁts (QALYs) for treatment and control groups, together
with their respective variances and co-variances were imputed.
For different values of threshold willingness to pay per additional
QALY, the relationship between sample size and statistical power
were determined. RESULTS: For a willingness to pay threshold
of £30,000 per additional QALY, a difference in costs DC =
£20,000, difference in beneﬁt DB = 1 QALY, variance in treat-
ment and control beneﬁt s2(B) = 10 QALYs, variance in treat-
ment and control cost s2(C) = £106 and covariance of DC and
DB set as zero, statistical power ranged from 8% for sample sizes
of 50 per arm to 65% for sample sizes of 1000 per arm. CON-
CLUSIONS: Certain diseases are sufﬁciently rare that even if 
all patients were included in a clinical trial, adequate statisti-
cal power for cost-effectiveness of treatments may never be
achieved. Further, trials for orphan drugs are often non-
comparative which also detracts from the reliance that may be
placed on inferences on clinical and /or cost-effectiveness. For
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